Published date: 11 November 2022

Closed opportunity - This means that the contract is currently closed. The buying department may be considering suppliers that have already applied, or no suitable offers were made.


Closing: 6 December 2022, 12pm

Contract summary

Industry

  • Research and experimental development services - 73100000

Location of contract

North West

Value of contract

£50,000 to £100,000

Procurement reference

BIP728172133

Published date

11 November 2022

Closing date

6 December 2022

Closing time

12pm

Contract start date

2 January 2023

Contract end date

31 December 2024

Contract type

Service contract

Procedure type

Open procedure

Any interested supplier may submit a tender in response to an opportunity notice.

Contract is suitable for SMEs?

Yes

Contract is suitable for VCSEs?

Yes

Description

STM, together with colleagues at the Department of Chemistry of the University of Liverpool (UoL), The University Hospital Bonn, the University of Buea in Cameroon and the Japanese pharmaceutical company Eisai, are developing a new drug to target the neglected tropical diseases lymphatic filariasis (LF) and onchocerciasis. These are both debilitating infections that affect more than 150 million people globally. The drug candidate, AWZ1066S is funded to enter a Phase II clinical trial in 2023 and the design of the trial requires the supply of Albendazole and an Albendazole placebo for use in the clinical trial.

More information

Links

Additional text

The contracting authority considers that this contract may be suitable for economic operators that are small or medium enterprises (SMEs). However, any selection of tenderers will be based solely on the criteria set out for the procurement.

About the buyer

Contact name

Liz Wilson

Address

Pembroke Place
Liverpool
Liverpool
L3 5QA
UK

Telephone

+441517053152

Email

tenders@lstmed.ac.uk